Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 18, 2000, Pages 3230-3239

  Thor, A D ^a   Liu, S ^a   Edgerton, S ^a   Moore II, D ^a   Kasowitz, K M ^a   Benz, C C ^a   Stern, D F ^a   DiGiovanna, M P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME;

EID: 0034666345     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.18.3230     Document Type: Article

References (48)

1. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185(neu/ErbB-2) in a subset of human breast cancers overexpressing this receptor
2. The erbB3 gene product is a receptor for heregulin
3. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade
4. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
5. Heregulin induces tyrosine phosphorylation of HER4/p180(erbB4)
6. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta
7. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, erbB-3, and erbB-4
8. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family
9. EGF-stimulated tyrosine phosphorylation of p185(neu): A potential model for receptor interactions
10. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/Neuregulin and epidermal growth factor
11. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
12. Increased expression of the putative growth factor receptor p185(HER2) causes transformation and tumorigenesis of NIH 3T3 cells
13. Oncogenic potential of ErbB-2 in human mammary epithelial cells
14. Oncogenic activation of p185(neu) stimulates tyrosine phosphorylation in vivo
15. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
16. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion
17. Molecular cloning of the neu gene: Absence of gross structural alteration in oncogenic alleles
18. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors
19. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
20. 2-terminally truncated HER-2/neu protein: Relationship with shedding of the extra-cellular domain and with prognostic factors in breast cancer
21. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor
22. A novel splice variant of HER2 with increased transformation activity
23. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
24. Membrane targeting of the nucleotide exchange factor Sos is sufficient for actvating the ras signaling pathway
25. Epidermal growth factor regulates p21(ras) through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor
26. Involvement of pp60(c-src) with two major signaling pathways in human breast cancer
27. SH2 domains recognize specific phosphopeptide sequences
28. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer
29. Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185(neu/ErbB-2) and the epidermal growth factor receptor
30. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
31. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain
32. Carbocyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product
33. The role of autophosphorylation in modulation of erbB-2 transforming function
34. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
35. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer - Experience from a large study with long term follow-up
36. Evaluation of in vitro bromodeoxyuridine labelling of breast carcinomas with the use of a commercial kit
37. pS2 protein and steroid hormone receptors in invasive breast carcinomas
38. ErbB-2, p53 and the efficacy of adjuvant therapy in lymph node positive breast cancer
39. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
40. Comparison of mitotic index, in vitro bromodeoxyruidine labeling, and MIB-1 assays to quantitative proliferation in breast cancer
41. Regression models and life-tables
42. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer
43. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
44. c-ErbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer
45. Prognostic factors in breast cancer